Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Government Contract opportunity was posted on August 20, 2012. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Evaluation of Risk of Narcolepsy/Pandemrix

Closed
2012-N-14596Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

AI Contract Overview

Show more

The Centers for Disease Control and Prevention intends to contract with the Brighton Collaboration in Switzerland to extend a scientific study evaluating the risk of narcolepsy associated with Pandemrix and Arepanrix vaccines. This project aims to build upon a multi-country European study to further assess the association between these specific adjuvanted and non-adjuvanted H1N1 vaccines and the development of narcolepsy across European and non-European countries, including Canada. Due to their role as the primary contractor for the initial study and their unique technical and administrative expertise in vaccine safety research, the Brighton Collaboration is identified as the sole source capable of satisfying the requirements. The anticipated period of performance for this effort is two years from the date of award.

General Info

Agency

N/A

Contract Value

$1,236,336

NAICS

541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)

Place of Performance

Europe, CHE

Set-Aside

NONE

Award Issued Date

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

3 updates
PhaseClosed
Posted

special-notice

Notice updated

Response deadline changed from Jul 13, 2012 to Aug 10, 2012. The notice description changed.

Notice updated

Response deadline changed from Aug 10, 2012 to Aug 30, 2012. The notice description changed.

Deadline changed

Response deadline changed from Aug 30, 2012 to Aug 10, 2012.

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyN/A
Contacts1 person available
OfficeN/A
Organization / Agency
N/A
Office AddressN/A
Contacts
Berta L Biltz

Full Description

Show more
The Centers for Disease Control and Prevention (CDC), contemplates entering into a contract with the Brighton Collaboration in Switzerland to conduct an extension of a scientific study to further evaluate the association between particular brands of the services to be acquired for the "Enhanced Evaluation of Risk of Narcolepsy Associated with Pandemrix and Arepanrix" project are the scientific and technical expertise and administrative capability to build upon the multi-country European CDC coordinated study (through VAESCO) to further assess the risk of narcolepsy following vaccination with Pandemrix, Arepanrix and potentially other adjuvanted and non-adjuvanted H1N1 vaccines in European and other non-European countries. The Brighton Collaboration is a global network dedicated to vaccine safety research with the mission to bring countries together to conduct vaccine safety research and support other vaccine safety initiatives . We are seeking to leverage an ongoing study in Europe conducted by the Brighton Collaboration to extend the current European study to gather additional data to better evaluate the condition of interest (risk of narcolepsy after receipt of Pandemrix and expanding to evaluate Arepanrix [Canada]). To the best of our knowledge, the Brighton Collaboration has been the primary contractor for the European study since the start of the study including planning, writing and implementing the study protocol they are uniquely situated to support our goal of enhancing the current study and enroll other countries to gain a better understanding of the current European findings. Therefore, it is considered to be the only source that can satisfy this requirement. The anticipated period of performance shall be two years from date of award. All questions/concerns about the RFP shall be submitted via e-mail to BBiltz@cdc.gov. The solicitation will be available for downloading when issued, approximately on July 26, 2012. It is your responsibility to keep up with additional postings regarding the RFP on the Fedbizopps Website. See Numbered Note 22.

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS